{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:03Z","timestamp":1792431663296,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","award":["CIN 13-414"],"award-info":[{"award-number":["CIN 13-414"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1UG1DA049444-01"],"award-info":[{"award-number":["1UG1DA049444-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["3UG1DA040316-04S3"],"award-info":[{"award-number":["3UG1DA040316-04S3"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019768","name":"FP7 Ideas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019768","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.drugalcdep.2025.112663","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T02:17:44Z","timestamp":1743128264000},"page":"112663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-4704","authenticated-orcid":false,"given":"Jacob D.","family":"Baylis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-4703","authenticated-orcid":false,"given":"Terri L.","family":"Jorgenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5251","authenticated-orcid":false,"given":"Haley E.","family":"Pals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0185-3256","authenticated-orcid":false,"given":"Catherine S.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-5013","authenticated-orcid":false,"given":"Michelle D.","family":"Colvard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veldana","family":"Alliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-6545","authenticated-orcid":false,"given":"Tera","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7814","authenticated-orcid":false,"given":"Lewei A.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-4390","authenticated-orcid":false,"given":"Jessica","family":"Wyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-1553","authenticated-orcid":false,"given":"Eric J.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-7624","authenticated-orcid":false,"given":"Hildi J.","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-8871","authenticated-orcid":false,"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112663_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.japh.2023.06.001","article-title":"Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act","volume":"63","author":"Adams","year":"2023","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"key":"10.1016\/j.drugalcdep.2025.112663_bib2","series-title":"American Society of Addiction Medicine Public Policy Statement on the Role of Pharmacists in Medications for Addiction Treatment","author":"American Society of Addiction Medicine","year":"2024"},{"key":"10.1016\/j.drugalcdep.2025.112663_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108715","article-title":"Beyond state scope of practice laws for advanced practitioners: additional supervision requirements for buprenorphine prescribing","volume":"138","author":"Andraka-Christou","year":"2022","journal-title":"J. Subst. Abus. Treat."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1592\/phco.27.4.481","article-title":"Clinical pharmacy services, pharmacy staffing, and hospital mortality rates","volume":"27","author":"Bond","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112663_bib5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S1086-5802(16)30373-4","article-title":"Community pharmacists as patient advocates: physician attitudes","volume":"38","author":"Bradshaw","year":"1998","journal-title":"J. Am. Pharm. Assoc. (Wash.)"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112663_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1331\/154434506776180658","article-title":"The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma","volume":"46","author":"Bunting","year":"2006","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112663_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","article-title":"Retention strategies for medications for opioid use disorder in adults: a rapid evidence review","volume":"15","author":"Chan","year":"2021","journal-title":"J. Addict. Med"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/YCO.0000000000000943","article-title":"Pharmacist-prescriber collaborative models of care for opioid use disorder: an overview of recent research","volume":"37","author":"Cheetham","year":"2024","journal-title":"Curr. Opin. Psychiatry"},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112663_bib9","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/MLR.0b013e3181e57962","article-title":"US pharmacists' effect as team members on patient care: systematic review and meta-analyses","volume":"48","author":"Chisholm-Burns","year":"2010","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112663_bib10","first-page":"228","article-title":"Pharmacists' role in buprenorphine management for opioid use disorder: a narrative review","volume":"5","author":"Cleary","year":"2022","journal-title":"JACCP: J. Am. Coll. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112663_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/00952990.2020.1832507","article-title":"Aims, development, and early results of an interdisciplinary primary care initiative to address patient vulnerabilities","volume":"47","author":"Codell","year":"2021","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.drugalcdep.2025.112663_bib12","unstructured":"Department of Veteran Affairs, 2024. VHA Handbook 1108.11(4), Clinical Pharmacy Services, www.va.gov\/vhapublications\/ViewPublication.asp?pub_ID=3120."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/ajhp\/zxaa405","article-title":"Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder","volume":"78","author":"DeRonne","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.drugalcdep.2025.112663_bib14","unstructured":"Drug Enforcement Administration 2024Mid-Level Practitioners Authorization by State. Accessed December 4, 2024\u3008https:\/\/www.deadiversion.usdoj.gov\/drugreg\/practioners\/practioners.html\u3009."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112663_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.drugalcdep.2025.112663_bib16","unstructured":"Giberson, S., Yoder, S., Lee, M.P.Giberson, S., Yoder, S., Lee, M.P. Improving Patient and Health System Outcomes through Advanced Pharmacy Practice. A Report to the U.S. Surgeon General. Office of the Chief Pharmacist. U.S. Public Health Service. Dec 2011.."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112663_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","article-title":"Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within veterans health administration facilities","volume":"41","author":"Gordon","year":"2020","journal-title":"Subst. Abus"},{"key":"10.1016\/j.drugalcdep.2025.112663_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109902","article-title":"Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration","volume":"248","author":"Gordon","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112663_bib19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.9740\/mhc.n183353","article-title":"Clinical psychiatric pharmacist involvement in an outpatient buprenorphine program","volume":"3","author":"Grgas","year":"2013","journal-title":"Ment. Health Clin."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112663_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36914","article-title":"Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for medicaid enrollees","volume":"6","author":"Hammerslag","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib21","first-page":"727","article-title":"Average daily dose trajectories for episodes of buprenorphine treatment for opioid use disorder","volume":"45","author":"Hayes","year":"2024","journal-title":"Subst. Use Addctn J."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/apc.2010.0324","article-title":"Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV","volume":"25","author":"Henderson","year":"2011","journal-title":"AIDS Patient care STDs"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112663_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1331\/JAPhA.2008.07108","article-title":"Clinical and economic outcomes of medication therapy management services: the Minnesota experience","volume":"48","author":"Isetts","year":"2008","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/08897077231203849","article-title":"Research priorities for expansion of opioid use disorder treatment in the community pharmacy","volume":"44","author":"Jarrett","year":"2023","journal-title":"Subst. Abus"},{"issue":"11","key":"10.1016\/j.drugalcdep.2025.112663_bib25","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1093\/ajhp\/zxae007","article-title":"Complexity of patients with mental healthcare needs cared for by mental health clinical pharmacist practitioners in Veterans Affairs","volume":"81","author":"Jasuja","year":"2024","journal-title":"Am. J. Health-Syst. Pharm."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112663_bib26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/09540121003668102","article-title":"Improving adherence and clinical outcomes through an HIV pharmacist's interventions","volume":"22","author":"Ma","year":"2010","journal-title":"AIDS Care"},{"issue":"22","key":"10.1016\/j.drugalcdep.2025.112663_bib27","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/ajhp\/zxad176","article-title":"Clinical pharmacist practitioners on primary care teams play an important role in caring for complex patients with diabetes","volume":"80","author":"Miller","year":"2023","journal-title":"Am. J. Health-Syst. Pharm."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.21037\/apm-23-488","article-title":"A narrative review of risk mitigation strategies in the management of opioids for chronic pain and palliative care in older adults: interprofessional collaboration with the pharmacist","volume":"13","author":"Mohammad","year":"2024","journal-title":"Ann. Palliat. Med"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112663_bib29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in Buprenorphine Treatment in the United States, 2009-2018","volume":"323","author":"Olfson","year":"2020","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.japh.2023.04.029","article-title":"Addressing buprenorphine bottlenecks in the context of MAT Act implementation: a shared responsibility","volume":"63","author":"Ostrach","year":"2023","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.japh.2022.03.006","article-title":"Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder","volume":"62","author":"Pals","year":"2022","journal-title":"J. Am. Pharm. Assoc."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112663_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/08897077231198679","article-title":"Care practices of mental health clinical pharmacist practitioners within an interdisciplinary primary care model for patients with substance use disorders","volume":"44","author":"Percy","year":"2023","journal-title":"Subst. Abus"},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112663_bib33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/M21-4011","article-title":"The management of substance use disorders: synopsis of the 2021 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline","volume":"175","author":"Perry","year":"2022","journal-title":"Ann. Intern Med"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112663_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/29767342231211428","article-title":"An implementation-focused qualitative exploration of pharmacist needs regarding an opioid use disorder screening and brief intervention","volume":"45","author":"Rao","year":"2024","journal-title":"Subst. Use Addctn J."},{"key":"10.1016\/j.drugalcdep.2025.112663_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/PPA.S30244","article-title":"The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review","volume":"6","author":"Saberi","year":"2012","journal-title":"Patient Prefer. adherence"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112663_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/08897077231186212","article-title":"Will the end of the X-waiver expand access to buprenorphine treatment? Achieving the full potential of the 2023 consolidated appropriations act","volume":"44","author":"Saloner","year":"2023","journal-title":"Subst. Abus"},{"key":"10.1016\/j.drugalcdep.2025.112663_bib37","article-title":"Building the primary care workforce with pharmacist clinical services","author":"Smith","year":"2024","journal-title":"Health Aff. Forefr"},{"key":"10.1016\/j.drugalcdep.2025.112663_bib38","doi-asserted-by":"crossref","DOI":"10.5888\/pcd17.200350","article-title":"Pharmacy contributions to improved population health: Expanding the public health roundtable","volume":"17","author":"Strand","year":"2020","journal-title":"Prev. Chronic Dis."},{"key":"10.1016\/j.drugalcdep.2025.112663_bib39","unstructured":"U.S. Department of Veterans Affairs. Types of Telehealth. \u3008https:\/\/telehealth.va.gov\/types-telehealth\u3009. Accessed November 22, 2024 ."},{"key":"10.1016\/j.drugalcdep.2025.112663_bib40","series-title":"Doctoral Dissertation","article-title":"Improving Access to Care for Veterans: Removing Barriers and Implementing Facilitators in Utilizing the VA Video Connect (VVC) in a Primary Care Setting","author":"Wicker","year":"2022"},{"issue":"7","key":"10.1016\/j.drugalcdep.2025.112663_bib41","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.112663_bib42","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1007\/s11606-024-08898-1","article-title":"Integrating buprenorphine for opioid use disorder into rural, primary care settings","volume":"39","author":"Wyse","year":"2024","journal-title":"J. Gen. Intern Med"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112663_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","article-title":"Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps","volume":"39","author":"Wyse","year":"2018","journal-title":"Subst. Abus"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625001164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:14:58Z","timestamp":1777565698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625001164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"alternative-id":["S0376871625001164"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112663","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112663"}}